Sign In
Buy ANIP
$82.07
-1.71 (-2.04%)
At Close: Jul 10, 2026
ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run
08:20pm, Sunday, 12'th Jul 2026
The executive disposed of 3,313 shares on July 2, 2026, for a total transaction value of about $285,000. The transaction represented 2% of the insider's total direct equity holdings in the company.
ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge
05:36pm, Thursday, 09'th Jul 2026
An ANI Pharmaceuticals executive reported selling 2,850 shares directly for about $240,000 on June 29, 2026. The sale represented 1.58% of Carey's direct holdings, reducing his direct stake to 177,543
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
10:46am, Thursday, 02'nd Jul 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple
10:26am, Friday, 26'th Jun 2026
ANI Pharmaceuticals is rated a speculative buy, with the investment thesis centered on Cortrophin Gel's rare disease revenue growth and transformation. Management guides to $540M-$575M Cortrophin reve
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
10:46am, Tuesday, 16'th Jun 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings?
02:30pm, Wednesday, 10'th Jun 2026
ANIP trades at 9.75x forward earnings after raising 2026 guidance, but investors must weigh Cortrophin-led growth against competition and customer concentration.
ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push
02:26pm, Wednesday, 10'th Jun 2026
ANIP expands Cortrophin into acute gout flares with a 90-person sales force as investors watch adoption, spending and 2026 milestones.
ANIP Pharmaceuticals' Cortrophin Gel Drives 2026 Growth
02:21pm, Wednesday, 10'th Jun 2026
ANI Pharmaceuticals ANIP is reshaping its growth profile. In 2025, revenue surged on the back of a rare disease franchise that is becoming the company's defining investment narrative.
Why ANI Pharmaceuticals (ANIP) is a Top Growth Stock for the Long-Term
10:46am, Friday, 29'th May 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
06:50am, Wednesday, 27'th May 2026
PRINCETON, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fire
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
12:51pm, Friday, 15'th May 2026
ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence.
ANIP Valuation: Does 9.8x Forward P/E Offer Upside?
12:47pm, Friday, 15'th May 2026
ANI Pharmaceuticals trades at 9.83x forward earnings, far below peers and its five-year median despite rising Rare Disease sales.
ANIP Stock: What's Driving Cortrophin Gel's 2026 Surge
12:40pm, Friday, 15'th May 2026
Cortrophin Gel is reshaping ANI Pharmaceuticals into a specialty-driven growth story, with 2026 revenue guidance signaling another major leap.
ANI Pharmaceuticals (ANIP) is a Top-Ranked Momentum Stock: Should You Buy?
10:51am, Wednesday, 13'th May 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million
05:09pm, Monday, 11'th May 2026
ANI Pharmaceuticals develops and manufactures branded and generic drugs for diverse North American healthcare markets.
